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BLETTER TO THE EDITOR
esenchymal Stem Cells Combined with Cyclosporine
nhibits Cytotoxic T Cells
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1Maccario and collaborators reported that mesen-
hymal stem cells (MSCs) and cyclosporine had a
ynergistic effect by inhibiting cytotoxic T-cell lysis of
arget cells, a ﬁnding that may have clinical implica-
ions [1]. This effect may explain some of the ﬁndings
e have seen in our patients who were treated for
herapy-resistant graft-versus-host disease (GVHD).
n theory, we expected MSCs to have only immuno-
ogic effects by inhibiting the afferent phase of allo-
eactivity and not the efferent phase, because MSCs
nhibited mixed lymphocyte cultures (MLCs) and the
evelopment of cytotoxic T cells, but not cytotoxicity
y already developed cytotoxic T cells [2]. In a boy
ho was treated for therapy-resistant, acute, grade IV
VHD and responded to MSCs, GVHD occurred
hen cyclosporine A (CsA) was discontinued after
inimal residual disease was detected in a bone mar-
ow aspirate, and we wanted to allow for a maximum
raft-versus-leukemia effect [3]. However, he re-
ponded promptly by reversal of severe GVHD of the
ut and liver a second time when CsA and MSC were
einstituted.
In our further experience of treating therapy-re-
istant GVHD, we found that, although most patients
ave had dramatic responses, some do not respond to
SC therapy [4]. Thus, our plan for patients who do
ot respond to MSC has been to add anti–interleu-
in-2 receptor antibodies or anti–T-cell globulin to
ombine MSCs with antibodies directed against cyto-
oxic T cells. However, in light of the ﬁndings of
accario et al [1], this appears to be unnecessary.
nstead, it may be dangerous to treat patients with
dditional immunosuppressive agents, because MSCs
nhibit T-cell responses not only to alloantigens and
itogens but also to infectious agents in vitro. We
ave also seen that some patients treated with MSCs
or severe GVHD have developed severe infectious
omplications such as disseminating cytomegalovirus,
aricella-zoster virus, adenovirus, and Aspergillus and
usarium infections [4]. In a patient who underwent a
hird transplantation due to previous rejections, MSCs
ere given because of therapy-resistant, extensive,
hronic GVHD [4]. Subsequently, this patient devel-
ped a gastrointestinal Epstein-Barr virus (EBV) lym-
B & M Thoproliferative disorder that did not respond to re-
eated treatment with EBV-speciﬁc cytotoxic T cells
5]. The reason for this unresponsiveness may have
een the synergistic effect of MSCs and CsA on EBV-
peciﬁc cytotoxic T cells. The synergistic effect be-
ween MSCs and CsA on cytotoxic T cells is beneﬁcial
n the context of alloreactivity, such as GVHD, but
ay be deleterious during a concurrent viral infection
n a severely immunocompromised patient.
We examined the synergistic effect of MSCs and
sA in lymphocytes stimulated by phytohemaggluti-
in (PHA) [6]. After lymphocyte stimulation with
HA, MSCs and CsA alone inhibited proliferation;
hen combined, there was an additive effect. This is
n contrast to the synergistic immunosuppressive ef-
ect of MSCs and CsA observed in MLCs by Maccario
t al [1]. However, we found that MSCs inhibit lym-
hocyte proliferation by PHA and by alloantigens by
ifferent immunologic mechanisms [7]. Thus, MSCs
ncreased levels of interleukin-2 and soluble interleu-
in-2 receptor in mixed lymphocyte cultures, whereas
evels decreased in PHA-stimulated lymphocytes. In-
erleukin-10 levels increased in MLCs cocultured with
SCs but were not affected in PHA-stimulated lym-
hocytes. Further, prostaglandins were important in
nhibition by MSCs when lymphocytes were stimu-
ated by PHA but not by alloantigens. Thus, studies
erformed on alloantigen stimulation, such as the
tudies performed by Maccario et al, may be more
linically relevant to patients who have received trans-
lants than studies on lymphocytes activated by PHA
nd other artiﬁcial mitogens. The ﬁndings of Mac-
ario et al suggest that, if MSCs are to be used for
reatment of various immunologic disorders, they
hould be combined with CsA to have an effect where
ytotoxic T cells are involved.
In conclusion, the ﬁnding of synergy between
SCs and CsA regarding cytotoxic T cells on alloge-
eic targets has importance for future strategies of
ow to use MSCs in the clinic.
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